SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
19796193
Source:
http://linkedlifedata.com/resource/pubmed/id/19796193
Search
Subject
(
58
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0439234
,
umls-concept:C1174773
,
umls-concept:C1522577
,
umls-concept:C2825032
pubmed:issue
1
pubmed:dateCreated
2010-1-18
pubmed:abstractText
This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19796193-20148800
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/7804028
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Allergens
,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized
,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin E
,
http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1398-9995
pubmed:author
pubmed-author:AdédoyinJJ
,
pubmed-author:AnkerstJJ
,
pubmed-author:JohanssonS G OSG
,
pubmed-author:NoppAnnaA
,
pubmed-author:POCHGG
,
pubmed-author:PalmqvistMM
pubmed:issnType
Electronic
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
56-60
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19796193-Adult
,
pubmed-meshheading:19796193-Aged
,
pubmed-meshheading:19796193-Allergens
,
pubmed-meshheading:19796193-Animals
,
pubmed-meshheading:19796193-Anti-Asthmatic Agents
,
pubmed-meshheading:19796193-Antibodies, Anti-Idiotypic
,
pubmed-meshheading:19796193-Antibodies, Monoclonal
,
pubmed-meshheading:19796193-Antibodies, Monoclonal, Humanized
,
pubmed-meshheading:19796193-Asthma
,
pubmed-meshheading:19796193-Basophils
,
pubmed-meshheading:19796193-Cats
,
pubmed-meshheading:19796193-Clinical Trials as Topic
,
pubmed-meshheading:19796193-Follow-Up Studies
,
pubmed-meshheading:19796193-Forced Expiratory Volume
,
pubmed-meshheading:19796193-Humans
,
pubmed-meshheading:19796193-Hypersensitivity
,
pubmed-meshheading:19796193-Immunoglobulin E
,
pubmed-meshheading:19796193-Middle Aged
,
pubmed-meshheading:19796193-Questionnaires
pubmed:year
2010
pubmed:articleTitle
After 6 years with Xolair; a 3-year withdrawal follow-up.
pubmed:affiliation
Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska Institute, Stockholm, Sweden.
pubmed:publicationType
Journal Article
,
Research Support, Non-U.S. Gov't